Syncona Shs GBP (GB:SYNC)
LSE:SYNC
Want to see GB:SYNC full AI Analyst Report?
Top Page
Syncona Shs GBP
(LSE:SYNC)
Select Model
Select Model
Rating:55Neutral
Price Target:
96.00 p
▲(2.24% Upside)
Action:Reiterated
Date:12/30/25
The score is held back primarily by highly volatile and recently weak financial performance and negative technical momentum. Offsetting this are a conservatively positioned balance sheet (no debt) and positive corporate actions aimed at returning capital and improving shareholder value, but losses (negative P/E) keep the overall risk/quality profile mid-range.
Positive Factors
Balance sheet strength
Zero reported debt materially lowers financial distress risk and gives management durable optionality to fund follow-on investments, support portfolio companies through clinical cycles, or execute buybacks/returns without refinancing. This cushion improves resilience over multiple biotech cycles and supports strategic capital allocation over the next 2–6 months and beyond.
Negative Factors
Earnings volatility
Sharp swings in reported earnings reduce predictability of returns and make operational planning and investor forecasting difficult. For an investment vehicle, volatile P&L driven by market revaluations or one-off events undermines assessment of recurring performance and raises execution risk for multi-quarter capital deployment and shareholder-return targets.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Zero reported debt materially lowers financial distress risk and gives management durable optionality to fund follow-on investments, support portfolio companies through clinical cycles, or execute buybacks/returns without refinancing. This cushion improves resilience over multiple biotech cycles and supports strategic capital allocation over the next 2–6 months and beyond.
Read all positive factors
Syncona Shs GBP (SYNC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
N/A
Dividend YieldN/A
Average Volume (3M)483.92K
Price to Earnings (P/E)―
Beta (1Y)0.31
Revenue Growth-31.72%
EPS Growth-404.64%
CountryUK
Employees1,050
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)-0.15
Shares Outstanding608,193,050
10 Day Avg. Volume510,558
30 Day Avg. Volume483,919
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)-7.82
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£49.14M
Syncona Shs GBP Business Overview & Revenue Model
Company Description
Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest i...
How the Company Makes Money
Syncona makes money by investing in and managing a portfolio of life sciences companies. The company's revenue model primarily involves generating returns from its investments in these companies, either through exits such as public offerings or ac...
Syncona Shs GBP Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 64.35M | -68.31M | 30.75M | -39.79M | 18.69M | 78.54M |
| Gross Profit | 20.00M | -68.31M | 14.10M | -51.91M | 3.68M | 78.54M |
| EBITDA | -74.69M | -143.16M | 3.79M | 0.00 | -1.94M | 0.00 |
| Net Income | -93.58M | -143.16M | 3.79M | -56.02M | 8.84M | 53.16M |
Balance Sheet | ||||||
| Total Assets | 1.03B | 1.06B | 1.25B | 1.27B | 1.33B | 1.34B |
| Cash, Cash Equivalents and Short-Term Investments | 213.00K | 1.11M | 261.00K | 11.00K | 276.00K | 14.00K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 13.77M | 11.79M | 12.22M | 13.76M | 23.55M | 38.12M |
| Stockholders Equity | 1.02B | 1.05B | 1.24B | 1.25B | 1.31B | 1.30B |
Cash Flow | ||||||
| Free Cash Flow | 5.88M | 0.00 | 20.47M | -265.00K | 262.00K | -3.00K |
| Operating Cash Flow | 30.03M | 43.91M | 20.47M | -265.00K | 262.00K | -3.00K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | -30.38M | -43.06M | -20.22M | 0.00 | 0.00 | 0.00 |
Syncona Shs GBP Technical Analysis
Positive
93.90
Price Trends
91.14
Positive
94.58
Positive
95.84
Positive
Market Momentum
1.67
Negative
76.44
Negative
94.08
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SYNC, the sentiment is Positive. The current price of 93.9 is above the 20-day moving average (MA) of 91.76, above the 50-day MA of 91.14, and below the 200-day MA of 95.84, indicating a bullish trend. The MACD of 1.67 indicates Negative momentum. The RSI at 76.44 is Negative, neither overbought nor oversold. The STOCH value of 94.08 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:SYNC.
Syncona Shs GBP Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £1.84B | 12.41 | 2.24% | 2.40% | 68.95% | 109.67% | |
72 Outperform | £1.42B | 4.19 | 14.60% | 9.91% | -21.74% | 58.92% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
67 Neutral | £122.81M | 21.20 | 1.79% | 3.29% | -9.37% | ― | |
63 Neutral | £992.37M | 2.30 | 8.81% | ― | 11.00% | ― | |
61 Neutral | £592.78M | 1.18 | 7.16% | ― | -35.12% | ― | |
55 Neutral | ― | -5.91 | -12.49% | ― | -31.72% | -404.64% |
* Financial Sector Average
GB:SYNC
Syncona Shs GBP
98.00
13.30
15.70%
GB:ASHM
Ashmore Group PLC
214.40
79.78
59.27%
GB:GROW
Molten Ventures
592.50
298.50
101.53%
GB:IPO
IP Group plc
67.10
23.60
54.25%
GB:MERC
Mercia Asset Management
29.00
2.14
7.97%
GB:CLDN
Caledonia Investments
358.00
3.67
1.03%
Syncona Shs GBP Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Syncona Wins Shareholder Backing for New Investment Policy and Board Refresh
Positive
Mar 3, 2026
Syncona shareholders have overwhelmingly approved a new investment policy and long-term incentive arrangements at a general meeting, with around 90 per cent of votes cast in favour of both resolutions. The changes signal a refreshed strategic and ...
Business Operations and StrategyProduct-Related Announcements
Syncona’s Quell Therapeutics Advances Lead CAR-Treg Autoimmune Therapy and Refocuses Pipeline
Positive
Mar 3, 2026
Syncona portfolio company Quell Therapeutics has begun a Phase I/II CHILL clinical trial of its lead autologous CAR-Treg therapy, QEL-005, in patients with rheumatoid arthritis and systemic sclerosis, following UK regulatory approval. Built on Que...
Business Operations and StrategyShareholder Meetings
Syncona Refines Investment Strategy and Incentives Ahead of Shareholder Vote
Positive
Feb 12, 2026
Syncona Limited has published a circular detailing a revised investment and capital allocation framework, as well as new long-term incentive arrangements for its investment manager, aimed at maximising shareholder value and creating a more sustain...
Business Operations and StrategyStock BuybackFinancial DisclosuresPrivate Placements and Financing
Syncona Posts Strong Q3 NAV Gains as Beacon Financing and Late‑Stage Pipeline Drive Outlook
Positive
Feb 5, 2026
Syncona reported a solid third quarter, with net assets rising to £1.06bn and NAV per share up 3.6% to 173.9p, driven by a 5% quarterly gain in its life sciences portfolio, notably a 20% uplift in Beacon Therapeutics following an oversubscrib...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.